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Abstract
Objective
Clinical, radiologic, and molecular analysis of patients with genomic deletions upstream of the
LMNB1 gene.
Methods
Detailed neurologic, MRI examinations, custom array comparative genomic hybridization
(aCGH) analysis, and expression analysis were performed in patients at different clinical
centers. All procedures were approved by institutional review boards of the respective
institutions.
Results
Five patients from 3 independent families presented at ages ranging from 32 to 52 years with
neurologic symptoms that included progressive hypophonia, upper and lower limb weakness
and spasticity, and cerebellar dysfunction and MRIs characterized by widespread white matter
alterations. Patients had unique nonrecurrent deletions upstream of the LMNB1, varying in size
from 250 kb to 670 kb. Deletion junctions were embedded in repetitive elements. Expression
analysis revealed increased LMNB1 expression in patient cells.
Conclusions
Our findings confirmed the association between LMNB1 upstream deletions and leukodys-
trophy previously reported in a single family, expanding the phenotypic and molecular de-
scription of this condition. Although clinical and radiologic features overlapped with those of
autosomal dominant leukodystrophy because of LMNB1 duplications, patients with deletions
upstream of LMNB1 had an earlier age at symptom onset, lacked early dysautonomia, and
appeared to have lesser involvement of the cerebellum and sparing of the spinal cord diameter
on MRI. aCGH analysis defined a smaller minimal critical region required for disease causation
and revealed that deletions occur at repetitive DNA genomic elements. Search for LMNB1
structural variants (duplications and upstream deletions) should be an integral part of the
investigation of patients with autosomal dominant adult-onset leukodystrophy.
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Autosomal dominant leukodystrophy (ADLD,OMIM#169500)
is a fatal, progressive neurologic disorder that presents in the
4th to 6th decade of life and primarily affects CNS myelin.1,2
Patients present with progressive autonomic dysfunction, fol-
lowed by disturbance of motor control as a result of cerebellar
deficits and spasticity; death occurs 10–20 years after the onset of
symptoms.2–4
We have previously shown that ADLD is caused by a duplication
of the lamin B1 gene (LMNB1, chr5q23.2), resulting in in-
creased LMNB1 protein expression.4,5 Although only LMNB1
duplications have been definitively shown to cause ADLD, we
recently identified a genomic deletion upstream of the LMNB1
gene in a single large pedigree (ADLD-1-TO) that resulted in an
phenotype similar to ADLD caused by LMNB1 duplications.6
As the mutation was identified in only a single family, it was
difficult to unequivocally confirm the link between the LMNB1-
associated deletions and the leukodystrophy phenotype.
In this report, we present the analysis of 3 novel families with
genomic deletions of varying sizes upstream of the LMNB1.
The identification of a larger cohort of patients allows us to
confirm the association between LMNB1 upstream deletions
and disease, define a broader phenotypic spectrum associated
with the mutation, and acquire mechanistic insights into the
cause of this genomic rearrangement.
Methods
Five patients, belonging to 3 independent families, were examined
because of adult-onset neurologic dysfunction. Array comparative
genomic hybridization (aCGH) using a custom array, bio-
informatics, and expression analysis was performed as described
earlier.4,6 Histopathologic analysis and brief clinical and MRI
findings from patient DEL2-1 have been described previously.7
Standard protocol approvals, registrations,
and patient consents
Clinical and radiologic evaluations took place under the
guidelines of the respective institutional review boards, and all
patients provided written informed consent.
Data availability statement
All data used in this study are included in this report or ac-
companying supplementary information.
Results
Clinical characteristics of the 5 patients are described in
table 1 and e-supplementary clinical information (links.
lww.com/NXG/A135). The age at onset of neurologic
symptoms ranged from 32 to 52 years. Presenting symp-
toms included dysarthria and hypophonia (4/5), poor
dexterity (4/5), imbalance (3/5), weakness of the ex-
tremities, including asymmetrical weakness (3/5), tremor
(2/5), and painful leg spasms (1). Of note, early involve-
ment of the autonomic nervous system was notable in
only 1 patient with orthostatic intolerance and urinary
urgency. In 2 patients, urinary urgency and incontinence
were late features of the disorder, occurring only after
development of severe lower limb spasticity. Two patients
indicated significant propensity for worsening of symp-
toms in relation to elevated environmental heat and
humidity.
Four patients underwent brain MRI (figure 1); all had
a corticospinal tract involvement extending from the upper
frontal lobes to the cerebral peduncles. Three patients
(DEL1-1, DEL2-1, and DEL3-1) had extensive symmetri-
cal white matter hyperintensities in all cerebral lobes with
a less affected periventricular rim on T2-weighted spin-
echo images. Patient DEL3-2 was unique, as she did not
exhibit extensive lobar involvement compared with other
patients. Of interest, the central parts of the pathologic
areas in this patient showed a low signal intensity (SI) on
T2-weighted fluid-attenuated inversion recovery images
indicating high fluid content. The upper cervical spinal cord
was seen in the sagittal brain images. The anteroposterior
diameters at C II were below the normal range in all
patients. MRI of the cervical and upper thoracic spine,
obtained in DEL3-1 and DEL2-1, did not reveal atrophy at
the lower levels, nor obvious SI alterations.
Patients were negative for mutations in known disease-
causing genes includingLMNB1 duplications (e-supplementary
clinical information, links.lww.com/NXG/A135). Sub-
sequent analysis using a custom aCGH assay allowed us
to identify and map deletions upstream of the LMNB1
gene (figure 2). Deletions were unique to each family and
ranged from ;670 kb to ;250 kb extending to within 88
kb–4.8 kb upstream of the LMNB1 start codon, respectively
(table e-1). Analysis of the deletion boundaries (including
those from the previously published ADLD-1-TO de-
letion) revealed that 3 of the 4 boundaries were in Alu
repeats. The telomeric end of the DEL3 deletion was sit-
uated in a long interspersed nucleotide element (LINE)
repeat element. A careful examination of the centromeric
end of this deletion revealed a 20-bp region that had a high
degree of homology to LINE elements. Thus, all the de-
letion boundaries appear to be embedded in some type of
Glossary
aCGH = array comparative genomic hybridization; ADLD = autosomal dominant leukodystrophy; LINE = long interspersed
nucleotide element; SI = signal intensity; TAD = topologically associated domain.
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repetitive DNA element. Expression analysis revealed in-
creased levels LMNB1 mRNA in cells from one of the
patients (Del1-1), consistent with the report on the ADLD-
TO family (table e-2).6
Discussion
Patients with deletions upstream of the LMNB1 gene had
clinical and radiologic signs that exhibited both unique findings
Table 1 Clinical data
Patient DEL1-1 DEL2-1 DEL3-1 DEL3-2 DEL3-3
Sex Male Male Female Female Male
Age at
symptom
onset (y)
34 52 37 34 32
Ethnicity East Asian Northern European Northern European/
Native American
Northern
European/Native
American
Northern European/
Native American
Living status
(age in years)
Alive (40) Deceased (59) Alive (42) Deceased (36) Deceased (50)
Presenting
complaint at
disease onset
Right hand tremor and
voice difficulties
Leg cramps and slowly
progressive spasticity
Hypophonia,
dysarthria, and hand
incoordination
Soft/slurred speech
and hand
incoordination
Decreased dexterity of
upper limb weakness
and dysarthria
Affect Normal Chronic anxiety Depressed mood Normal Pseudobulbar affect
Oral motor
control and
articulation
Soft “breathy” and halting
voice and dysphagia
Speech was normal Muffled voice,
unilateral facial
weakness, and
drooling
Speech apraxia and
dysphagia
Dysarthria
Eye and
extraocular
movement
examination
Normal Fine end-point nystagmus on
lateral gaze. Interrupted
saccades, in vertical and
horizontal planes
Normal dilated
examination,
Saccadic intrusion
Optic disk pallor,
limited up-gaze and
saccadic intrusion
Normal
Motor
examination
Head and hand tremor
(asymmetrical),
incoordination and
spastic and ataxic gait,
and weakness of lower
extremities
Tremor of lower extremities,
spasticity, and cerebellar
deficits
Asymmetrical spastic
weakness of upper
and lower extremities
Asymmetrical (left >
right) spastic
weakness of upper
and lower
extremities
Decreased dexterity
upper limb spasticity and
asymmetrical weakness
of both upper and lower
limbs (right > left)
DTRs/plantar
responses
Brisk with clonus/
extensor
Spastic in all limbswith lower
limb clonus; positive
Hoffman response
Lower extremity
clonus/extensor
Brisk Brisk/extensor
Sensory
examination
Normal Normal Normal Normal Normal
Autonomic
nervous
system
Early orthostatic
intolerance and urinary
urgency
Late urinary urgency and
incontinence
Normal by history
and laboratory
testinga
Normal by history Late urinary urgency
EMG/NCV NA Normal Normal L peroneal
entrapment
neuropathy
NA
Family
history and
inheritance
patters
Negative Positive/autosomal
dominant
Positive/autosomal
dominant
Positive/autosomal
dominant
Positive/autosomal
dominant
Comorbidities Migraines, gout, and
dyslipidemia
Hypertension, GERD, and
DJD
None None None
Other Neurologic deficits
worsened with
respiratory infection
Snout reflex Neurologic deficits
reported to be
worsened by
environmental heat
Dyspnea likely from
neuromuscular
weakness; L leg
pain likely from
peroneal
neuropathy
Neurologic deficits
reported to be worsened
by environmental heat
Abbreviations: DJD = degenerative joint disease; DTR = deep tendon reflex; GERD = gastroesophageal reflux disease; NA = not available; NCV = nerve
conduction velocity.
a Included R-R variability, Tilt-table test, Valsalva maneuver, and sudomotor axon reflex test.
Neurology.org/NG Neurology: Genetics | Volume 5, Number 1 | February 2019 3
and partial overlap with ADLD due to LMNB1 duplications.
Clinically, 4/5 patients presented at onset with speech symp-
toms including dysarthria and hypophonia. This has not been
reported for ADLD with LMNB1 duplications, where the
most common presenting feature was autonomic dysfunction.
Onset of symptoms also appeared to be earlier in patients with
deletions.
On MRI, cerebral white matter involvement was more ex-
tensive, especially in the temporal lobes in patients with
deletions compared with those with duplications at the same
ages. The periventricular rim was less severely affected than
other pathologic lobar white matter in both patient groups.
The corticospinal tracts were affected in both groups, but only
in one of the deletion patients (DEL1-1) did this extend to the
medulla oblongata. This was the only 1 of the 4 deletion
patients having an abnormality in the cerebellar peduncles.
This is in contrast to duplication patients who have early
changes in the medulla oblongata and cerebellar peduncles.2
Cerebral atrophy is not a prominent feature in patients with
duplications, but marked atrophy was found in 1 of our
patients (DEL 2-1) and in the previously reported Italian
ADLD-1-TO family.8 In patients with deletions, only the
uppermost cervical spinal cord was atrophic, and in the 2
patients with a spinal MRI, no obvious SI changes were found
in the rest of the cord. In LMNB1 duplication patients, the
entire spinal cord is atrophic, and T2 signal in white matter is
pathologic. This difference could explain the lack of early
autonomic symptoms in patients with deletions, as it has been
hypothesized that autonomic symptoms in ADLD with
duplications are due to spinal cord involvement.2
Analysis of the deletion events, which were clearly nonrecurrent,
allowed us to define a minimal critical region of ;167 kb that
is required for disease causation. Strikingly, this genomic re-
gion encompassed a boundary between 2 topologically associated
Figure 1 Brain MRI features in patients with deletions upstream of LMNB1
All images are T2-weighted. (A) Patient DEL1-1 had the most extensive changes. Very high SI in the frontal, parietal, occipital, and temporal white matter and
even juxtacortical areaswere pathologic (A.a–A.d). The periventricular areawas less affected on SE images (A.a, A.b, arrows) but exhibited a very high signal on
FLAIR images. The entire posterior limb of the internal capsule was pathologic (A.c, arrowhead). The corticospinal tract (open arrow) had a high SI also in the
cerebral crura (A.d), pons (A.e), and pyramids of the medulla oblongata (A.f). High SI in the decussation of the superior cerebellar peduncles (A.d, open
arrowhead) and in the middle cerebellar peduncles was observed (A.e, star). The splenium was thin and revealed a high T2 signal (not shown). Patients (B)
DEL2-1 and (C) DEL3-1 have less extensive changes in lobar whitematter (B.a–B.e, C.a–C.e). The periventricular areawas less affected both in the SE and FLAIR
images (B.a and B.b, C.a and C.b, arrows). High SI continued in the corticospinal tract (open arrows) in the internal capsule (B.c and C.c) and the cerebral crura
in themesencephalon (B.d and C.d). Diffusely increased SI was also present in the upper pons (B.e and C.e). Decussations of the superior cerebellar peduncles
(B.d and C.d, open arrowhead) had a high SI (B.d and C.d, open arrow). Patient DEL2-1 had larger mesencephalic SI changes (B.d) compared with the other
patients. This patient also had cerebral atrophy: very broad third ventricle (B.c), widened lateral ventricles (B.b), and cerebral sulci (B.a–B.e). (D) Patient DEL 3-2
had abnormalities distinct from other patients; the SI was very high locally in the posterior frontal lobes, including corticospinal tracts, on the SE images (D.a
and D.b). On the FLAIR images, the central parts of the pathologic areas showed a low SI as a sign of a high fluid content. There were some small separate
frontal and parietal lesions that may be of the same or another etiology, whereas very small occipital changes (D.c) were present. The high SI continued
downward in the corticospinal tract (D.c and D.d, open arrows) until the cerebral crura but not further. Increased SI in the decussation of the superior
cerebellar peduncles was observed (D.d, open arrowhead). FLAIR = fluid-attenuated inversion recovery; SE = conventional or turbo spin-echo sequence; SI =
signal intensity.
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domains (TADs) and strengthens our original hypothesis that
a disruption of the TAD boundary causes LMNB1 over-
expression and in turn the disease.6 Sequencing the deletion
junctions revealed the importance of repetitive elements (Alu,
LINEs) in the genomic rearrangement. Their presence suggests
that either a nonallelic homologous recombinationmechanismor
a microhomology-mediated break-induced repair type mecha-
nismmediated by repeats is likely to cause the genomic deletions.
The identification of a larger cohort of patients confirms the
pathogenic role of deletions upstream of LMNB1 in the leu-
kodystrophy phenotype. Given that these mutations do not
alter the coding sequence, our data also emphasize the im-
portance of regulatory elements and the need for performing
analyses for copy number variants that might be missed with
the standard whole-exome sequencing, currently being used
to identify mutations in patients with leukodystrophies.
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